Cargando…

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome

BACKGROUND: To identify predictors of long-term outcome for patients with clinical complete response (cCR) after definite chemoradiotherapy (CRT) or radiation therapy (RT) for oesophageal cancer (EC). METHODS: In this retrospective study, we reviewed the files of all patients from our institution th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adenis, Antoine, Tresch, Emmanuelle, Dewas, Sylvain, Romano, Olivier, Messager, Mathieu, Amela, Eric, Clisant, Stéphanie, Kramar, Andrew, Mariette, Christophe, Mirabel, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844443/ https://www.ncbi.nlm.nih.gov/pubmed/24010566 http://dx.doi.org/10.1186/1471-2407-13-413

Ejemplares similares

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
por: Messager, Mathieu, et al.
Publicado: (2016)

Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking
por: Jarraya, Hajer, et al.
Publicado: (2013)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy
por: Dewas, Sylvain, et al.
Publicado: (2012)

A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases
por: Fumagalli, Ingrid, et al.
Publicado: (2012)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2013)

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
por: Dewas, Claire Vautravers, et al.
Publicado: (2012)

Chemoradiation for oesophageal cancer: the choice of treatment modality
por: Kitti, Pauliina M., et al.
Publicado: (2023)

Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas – PRODIGE 19 – FFCD1103 – ADCI002
por: Piessen, Guillaume, et al.
Publicado: (2013)

Combined modality chemoradiation in elderly oesophageal cancer patients
por: Anderson, S E, et al.
Publicado: (2007)

Adjuvant radiation therapy in metastatic lymph nodes from melanoma
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2011)

Isolated granulocytic sarcoma of the pancreas: A tricky diagnostic for primary pancreatic extramedullary acute myeloid leukemia
por: Messager, Mathieu, et al.
Publicado: (2012)

Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation
por: Ajani, J A
Publicado: (2008)

Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation
por: Gillham, Charles M, et al.
Publicado: (2007)

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers
por: Mariette, Christophe, et al.
Publicado: (2018)

Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results
por: Dewas, Sylvain, et al.
Publicado: (2011)

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials
por: Kotecki, Nuria, et al.
Publicado: (2012)

Reply: molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation
por: Yoshikawa, R, et al.
Publicado: (2008)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases
por: Penel, Nicolas, et al.
Publicado: (2008)

Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation
por: Schernberg, Antoine, et al.
Publicado: (2017)

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer
por: Conroy, T, et al.
Publicado: (2010)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
por: Pannier, Diane, et al.
Publicado: (2018)

Adapted Prescription Dose for Monte Carlo Algorithm in Lung SBRT: Clinical Outcome on 205 Patients
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2015)

Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report
por: Mei, Zhu, et al.
Publicado: (2018)

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program
por: Adenis, Antoine, et al.
Publicado: (2016)

Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
por: Adenis, Antoine, et al.
Publicado: (2016)

Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma
por: Haj Mohammad, Nadia, et al.
Publicado: (2014)

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus
por: Münch, Stefan, et al.
Publicado: (2019)

(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response
por: Gillham, C M, et al.
Publicado: (2006)

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study
por: van Meerten, E, et al.
Publicado: (2006)

Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring (18)F-FDG-PET/CT
por: Meijer, Tineke W.H., et al.
Publicado: (2018)

Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer
por: Tougeron, D, et al.
Publicado: (2008)

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
por: Sridharan, Vishwajith, et al.
Publicado: (2016)

A Case Report of an Early Response to Definitive Chemoradiation for Esophageal Carcinoma Cuniculatum
por: Long, David E., et al.
Publicado: (2020)

Definitive Chemoradiation With Dose Escalation for Locally Advanced Gastric Cancer: Case Studies
por: Anthony, Michelle, et al.
Publicado: (2020)

Outcomes by time to definitive chemoradiation treatment for patients with muscle-invasive bladder cancer
por: Kotha, Nikhil V., et al.
Publicado: (2022)

Factors predictive of parametrial boost in patients with cervical cancer treated with definitive chemoradiation
por: Jamora, Kurl E., et al.
Publicado: (2022)

Gastrointestinal Cancer Found in the Cervix With Unknown Primary Site and Treated With Definitive Chemoradiation
por: Albana, Jasen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6kvvlmf2f5iela134t5d71hpj1